Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Res. 2014 Jun;38(6):666-72. doi: 10.1016/j.leukres.2014.02.009. Epub 2014 Mar 13.

Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival.

Author information

  • 1State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, People's Republic of China.
  • 2Department of Diagnostics, College of Basic Medical Science, Tianjin Medical University, Tianjin 300070, People's Republic of China.
  • 3The First Affiliated Hospital of Nanchang University, 30006 Nanchang, Jiangxi, People's Republic of China.
  • 4Department of Laboratory Hematology, University Health Network, University of Toronto, Canada.
  • 5State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, People's Republic of China. Electronic address: drqiu99@medmail.com.cn.

Abstract

Normal plasma cells (PCs) are either undetectable or outnumbered by the myelomatous PC compartment in bone marrow of multiple myeloma (MM). However, residual normal PCs have been detected in a minority of symptomatic MM patients with superior survival. The number of normal PCs is also an important factor to identify monoclonal gammopathy of undetermined significance (MGUS)-like MM. We speculate that the polyclonal serum IgM level in non-IgM myelomas may reflect the number of residual normal PCs. Here we investigated the prognostic relevance of polyclonal serum IgM level in a series of 485 newly diagnosed symptomatic MM (NDMM) patients. Our results showed that symptomatic MM patients with polyclonal IgM more than 0.5g/L displayed a favorable baseline clinical feature, together with a significantly lower frequency of high-risk cytogenetic abnormalities. This group of patients had a significantly prolonged progression-free survival (PFS) and overall survival (OS) regardless of thalidomide or bortezomib therapy. Furthermore, the superior outcome was independent of the depth of response. Our findings suggest that polyclonal IgM level is capable of identifying a group of symptomatic MM patients with distinct clinicobiological characteristics and favorable survival, similar with MGUS-like MM.

Copyright © 2014 Elsevier Ltd. All rights reserved.

KEYWORDS:

MGUS-like; Multiple myeloma; Polyclonal IgM; Residual normal plasma cells

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk